Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome.

International journal of hematology - 1 Jun 2023

Kataoka Asami, Mizumoto Chisaki, Kanda Junya, Iwasaki Makoto, Sakurada Maki, Oka Tomomi, Fujimoto Masakazu, Yamamoto Yosuke, Yamashita Kohei, Nannya Yasuhito, Ogawa Seishi, Takaori-Kondo Akifumi

Abstract excerpt

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is caused by UBA1 somatic mutations and is characterized by late-onset systemic autoimmune inflammation and blood abnormalities such as cytopenia, vacuolation of myeloid/erythroblastic cells, and myelodysplastic syndrome (MDS). It is often resistant to immunosuppressive therapy, and no treatment strategy has been established. A 65-year-old...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Azacitidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Exanthema

Share to Inflammation

Share to Myelodysplastic Syndromes

Share to Skin Diseases, Genetic

Source

Identifiers

PMID: 36641501
DOI: 10.1007/s12185-023-03532-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome.PMID 36641501Read ↗

Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registrySemantic proximity Read ↗

VEXAS syndrome in myelodysplastic syndrome with autoimmune disorderSemantic proximity Read ↗

Case report: diagnosis of VEXAS syndrome in a patient with therapy-resistant large vessel vasculitis.Semantic proximity Read ↗

Hypomethylating agents in vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review.Semantic proximity Read ↗

UBA1 and DNMT3A mutations in VEXAS syndrome. A case report and literature review.Semantic proximity Read ↗

Trisomy 8 clonal expansion during disease progression and azacitidine resistance in VEXAS syndrome: a case report.Semantic proximity Read ↗

Looking beyond VEXAS: Coexistence of undifferentiated systemic autoinflammatory disease and myelodysplastic syndrome.Semantic proximity Read ↗

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel.Semantic proximity Read ↗

Systemic inflammation with myelodysplastic features: VEXAS syndrome.Semantic proximity Read ↗

VEXAS syndrome in adults: A narrative review of genomic pathogenesis, multisystem phenotypes, diagnostic algorithms, and emerging therapeutic strategies.Semantic proximity Read ↗

Clonal hematopoiesis meets an autoinflammatory disease: the new paradigm of VEXAS syndrome.Semantic proximity Read ↗

VEXAS syndrome: Clinical manifestations, diagnosis, and treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.